$ 5.27
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
In Guru Portfolios
Data is available to registered users only
Data is available to registered users only
Portfolio Weight (%)
Data is available to registered users only
Change
Data is available to registered users only
Fund
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Portfolio Weight (%)
Data is available to registered users only
Change
Data is available to registered users only
Fund
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Portfolio Weight (%)
Data is available to registered users only
Change
Data is available to registered users only
Fund
Data is available to registered users only
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
About
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Data is available to registered users only